WO2018011166A3 - Methods for quantifying the population of myeloid dendritic cells in a tissue sample - Google Patents

Methods for quantifying the population of myeloid dendritic cells in a tissue sample Download PDF

Info

Publication number
WO2018011166A3
WO2018011166A3 PCT/EP2017/067327 EP2017067327W WO2018011166A3 WO 2018011166 A3 WO2018011166 A3 WO 2018011166A3 EP 2017067327 W EP2017067327 W EP 2017067327W WO 2018011166 A3 WO2018011166 A3 WO 2018011166A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell populations
quantifying
population
dendritic cells
tissue sample
Prior art date
Application number
PCT/EP2017/067327
Other languages
French (fr)
Other versions
WO2018011166A2 (en
Inventor
Wolf Herman Fridman
Etienne BECHT
Aurélien De Reynies
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université Pierre Et Marie Curie (Paris 6)
Université Paris Diderot - Paris 7
Université Paris Descartes
Ligue Nationale Contre Le Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université Pierre Et Marie Curie (Paris 6), Université Paris Diderot - Paris 7, Université Paris Descartes, Ligue Nationale Contre Le Cancer filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2018011166A2 publication Critical patent/WO2018011166A2/en
Publication of WO2018011166A3 publication Critical patent/WO2018011166A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to methods for quantifying the population of myeloid dendritic cells in a tissue sample. The tumor microenvironment is a complex tissue which contains many distinct cell populations, and whose composition may predict prognosis and response to therapies. In the present disclosure, using samples of purified cell populations, the inventors defined specific and robust transcriptomic markers of the immune and stromal cell populations of the tumor microenvironment, and they quantitatively validated them in an in-vitro RNA mixture model. More, they developed the 'Microenvironment Cell Populations-counter' (MCP-counter) method, which, using transcriptomic data, allows a robust quantification of the abundance of immune and stromal populations in cellularly heterogeneous healthy and cancerous tissues. Thus, the present invention relates to a method for quantifying the population of myeloid dendritic cells in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CD1E, CLEC10A, CLIC2, CD1A, WFDC21P and CD1B.
PCT/EP2017/067327 2016-07-12 2017-07-11 Methods for quantifying the population of myeloid dendritic cells in a tissue sample WO2018011166A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305889 2016-07-12
EP16305889.4 2016-07-12

Publications (2)

Publication Number Publication Date
WO2018011166A2 WO2018011166A2 (en) 2018-01-18
WO2018011166A3 true WO2018011166A3 (en) 2018-02-22

Family

ID=56511490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/067327 WO2018011166A2 (en) 2016-07-12 2017-07-11 Methods for quantifying the population of myeloid dendritic cells in a tissue sample

Country Status (1)

Country Link
WO (1) WO2018011166A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111910000B (en) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis
US20220143220A1 (en) * 2020-10-19 2022-05-12 Washington University Compositions and methods for modulating myc target protein 1

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
KR960703622A (en) 1993-07-15 1996-08-31 수잔 포오덴 PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
BR9708640B1 (en) 1996-04-12 2013-06-11 irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them.
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6617583B1 (en) 1998-09-18 2003-09-09 Massachusetts Institute Of Technology Inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60042738D1 (en) 1999-05-07 2009-09-24 Life Technologies Corp PROCESS FOR DETECTING ANALYTES USING SEMICONDUCTOR ANOCRYSTALLES
EP1206260A4 (en) 1999-06-30 2002-10-30 Merck & Co Inc Src kinase inhibitor compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Src kinase inhibitor compounds
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EE200200123A (en) 1999-09-10 2003-08-15 Merck & Co., Inc. A tyrosine kinase inhibiting compound, a pharmaceutical composition comprising it, and a therapeutic use
DZ3223A1 (en) 1999-10-19 2001-04-26 Merck & Co Inc TYROSINE KINASES INHIBITORS
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60018782T2 (en) 1999-10-19 2006-04-06 Merck & Co., Inc. TYROSINE KINASE INHIBITORS
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001249386A1 (en) 2000-03-22 2001-10-03 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
ATE415399T1 (en) 2000-08-04 2008-12-15 Molecular Probes Inc CONDENSED RINGS CONTAINING 1,2-DIHYDRO-7-HYDROXYCHINOLINE DERIVATIVES
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
WO2003000687A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
WO2003092043A2 (en) 2001-07-20 2003-11-06 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents that modulate immune cell activation and methods of use thereof
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
CN1753912B (en) 2002-12-23 2011-11-02 惠氏公司 Antibodies against PD-1 and uses therefor
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
ES2330441T3 (en) 2003-06-24 2009-12-10 Ventana Medical Systems, Inc. METAL DEPOSIT CATALYZED BY AN ENZYME FOR IMPROVED IN SITU DETECTION OF IMMUNOHISTOCHEMICAL EPITHOPES AND NUCLEIC ACID SEQUENCES.
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
AU2006239154A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc Nanoparticle conjugates
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007062177A2 (en) 2005-11-23 2007-05-31 Ventana Medical Systems, Inc. Molecular conjugate
AU2006330830B2 (en) 2005-12-23 2013-01-10 Institute For Systems Biology Nanoreporters and methods of manufacturing and use thereof
EP1963500B1 (en) 2005-12-23 2013-02-13 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
ES2437327T3 (en) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Antibodies for the human programmed PD-1 receptor of programmed death
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
ES2614810T3 (en) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Stable nano-indicators
KR102097887B1 (en) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
BRPI0917592B1 (en) 2008-12-09 2021-08-17 Genentech, Inc ANTI-PD-L1 ANTIBODY, COMPOSITION, MANUFACTURED ARTICLES AND USES OF A COMPOSITION
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
JP2013532153A (en) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LE NAOUR FRANCOIS ET AL: "Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 276, no. 21, 25 May 2001 (2001-05-25), pages 17920 - 17931, XP002236582, ISSN: 0021-9258, DOI: 10.1074/JBC.M100156200 *
M. VAN SETERS ET AL: "Disturbed Patterns of Immunocompetent Cells in Usual-Type Vulvar Intraepithelial Neoplasia", CANCER RESEARCH, vol. 68, no. 16, 15 August 2008 (2008-08-15), US, pages 6617 - 6622, XP055412726, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0327 *
MARK J. BLUTH ET AL: "Myeloid Dendritic Cells from Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY : OFFICIAL JOURNAL OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY AND THE EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH, vol. 129, no. 10, 1 October 2009 (2009-10-01), US, pages 2451 - 2462, XP055412825, ISSN: 0022-202X, DOI: 10.1038/jid.2009.96 *
MATTHEW COLLIN ET AL: "Human dendritic cell subsets", IMMUNOLOGY, vol. 140, no. 1, 12 August 2013 (2013-08-12), GB, pages 22 - 30, XP055412597, ISSN: 0019-2805, DOI: 10.1111/imm.12117 *
NAVIN R. MAHADEVAN ET AL: "Cell-Extrinsic Effects of Tumor ER Stress Imprint Myeloid Dendritic Cells and Impair CD8+ T Cell Priming", PLOS ONE, vol. 7, no. 12, 18 December 2012 (2012-12-18), pages e51845, XP055412926, DOI: 10.1371/journal.pone.0051845 *
VISKAM WIJEWARDANA ET AL: "Accumulation of functionally immature myeloid dendritic cells in lymph nodes of rhesus macaques with acute pathogenic simian immunodeficiency virus infection", IMMUNOLOGY, vol. 143, no. 2, 8 September 2014 (2014-09-08), GB, pages 146 - 154, XP055412827, ISSN: 0019-2805, DOI: 10.1111/imm.12295 *

Also Published As

Publication number Publication date
WO2018011166A2 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
Baslan et al. Unravelling biology and shifting paradigms in cancer with single-cell sequencing
Petrelli et al. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC)
Waddell et al. Gene expression profiling of formalin‐fixed, paraffin‐embedded familial breast tumours using the whole genome‐DASL assay
Kang et al. Possible biomarkers for ionizing radiation exposure in human peripheral blood lymphocytes
Abramovitz et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay
Pedersen et al. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma
US20140113978A1 (en) Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
Enkelmann et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer
Bae et al. Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts
KR20080065476A (en) A method of predicting risk of lung cancer recurrence in a patient after lung cancer treatment or a lung cancer patient, a method of preparing a report on the risk of lung cancer recurrence in a patient after lung cancer treatment or a lung cancer patient and a report prepared by the same, a composition, kit and microarray for diagnosing the risk of lung cancer recurrence in a patient after lung cancer treatment or a lung cancer patient
CN110257494B (en) Method and system for obtaining individual ages of Chinese population and amplification detection system
CN104032001B (en) ERBB signal pathway mutation targeted sequencing method for prognosis evaluation of gallbladder carcinoma
Rossing Classification of follicular cell-derived thyroid cancer by global RNA profiling
WO2019074615A2 (en) In vitro methods for skin therapeutic compound discovery using skin age biomarkers
WO2013025322A2 (en) Marker-based prognostic risk score in liver cancer
Magbanua et al. Advances in genomic characterization of circulating tumor cells
US20210139984A1 (en) Cell contamination assay
Magbanua et al. Approaches to isolation and molecular characterization of disseminated tumor cells
Abdulmawjood et al. Liquid biopsies in myeloid malignancies
WO2018011166A3 (en) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
Bertz et al. Urothelial bladder cancer: An update on molecular pathology with clinical implications
Riedmaier et al. The physiological way: monitoring RNA expression changes as new approach to combat illegal growth promoter application
Chen et al. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer
Rodrigues et al. Buffering of transcription rate by mRNA half-life is a conserved feature of Rett syndrome models
US11293065B2 (en) Compositions and methods for the quality control of stem cell preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17749125

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17749125

Country of ref document: EP

Kind code of ref document: A2